Bain Capital Life Sciences Fund, L.P.

revealed that they own a 26.4% stake in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) in a Schedule 13D/A disclosure that was filed with the Securities and Exchange Commission on Monday, September 18th. The investor owns 7,459,625 shares of the stock valued at $29,763,904. The reporting parties listed on the disclosure included Bain Capital Life Sciences Fund, LP and BCIP Life Sciences Associates, LP. The filing is available through Edgar at this hyperlink.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the stock. EcoR1 Capital LLC boosted its position in Dicerna Pharmaceuticals by 101.0% during the second quarter. EcoR1 Capital LLC now owns 767,992 shares of the biopharmaceutical company’s stock worth $2,435,000 after acquiring an additional 385,992 shares during the last quarter. Palo Alto Investors LLC boosted its position in Dicerna Pharmaceuticals by 4.0% during the second quarter. Palo Alto Investors LLC now owns 500,913 shares of the biopharmaceutical company’s stock worth $1,588,000 after acquiring an additional 19,394 shares during the last quarter. Vanguard Group Inc. boosted its position in Dicerna Pharmaceuticals by 4.5% during the second quarter. Vanguard Group Inc. now owns 340,327 shares of the biopharmaceutical company’s stock worth $1,078,000 after acquiring an additional 14,517 shares during the last quarter. Northern Trust Corp boosted its position in Dicerna Pharmaceuticals by 6.1% during the second quarter. Northern Trust Corp now owns 36,219 shares of the biopharmaceutical company’s stock worth $114,000 after acquiring an additional 2,094 shares during the last quarter. Finally, Bourgeon Capital Management LLC boosted its position in Dicerna Pharmaceuticals by 188.9% during the second quarter. Bourgeon Capital Management LLC now owns 39,000 shares of the biopharmaceutical company’s stock worth $124,000 after acquiring an additional 25,500 shares during the last quarter. Hedge funds and other institutional investors own 55.49% of the company’s stock.

Shares of Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) traded up 2.05% during trading on Monday, hitting $3.99. 199,400 shares of the company’s stock were exchanged. Dicerna Pharmaceuticals, Inc. has a 1-year low of $2.42 and a 1-year high of $6.10. The stock’s 50 day moving average is $3.38 and its 200 day moving average is $3.21. The firm’s market capitalization is $83.17 million.

Dicerna Pharmaceuticals (NASDAQ:DRNA) last announced its quarterly earnings data on Thursday, August 10th. The biopharmaceutical company reported ($1.15) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.61) by ($0.54). Dicerna Pharmaceuticals had a negative net margin of 8,474.12% and a negative return on equity of 168.65%. The company had revenue of $0.25 million for the quarter, compared to analysts’ expectations of $0.08 million. During the same period in the previous year, the firm posted ($0.75) earnings per share. The business’s revenue for the quarter was up 2400.0% on a year-over-year basis. On average, equities research analysts forecast that Dicerna Pharmaceuticals, Inc. will post ($2.70) earnings per share for the current year.

DRNA has been the topic of a number of analyst reports. Chardan Capital restated a “hold” rating on shares of Dicerna Pharmaceuticals in a research report on Monday, August 14th. ValuEngine upgraded shares of Dicerna Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, July 22nd. Zacks Investment Research lowered shares of Dicerna Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, July 18th. Finally, HC Wainwright restated a “buy” rating and set a $5.00 target price on shares of Dicerna Pharmaceuticals in a research report on Tuesday, May 23rd. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the stock. The company currently has an average rating of “Hold” and an average price target of $6.35.

ILLEGAL ACTIVITY WARNING: “Bain Capital Life Sciences Fund, L.P. Has Stake in Dicerna Pharmaceuticals, Inc. (DRNA)” was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of US & international trademark and copyright laws. The legal version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/09/18/bain-capital-life-sciences-fund-l-p-has-stake-in-dicerna-pharmaceuticals-inc-drna.html.

Dicerna Pharmaceuticals Profile

Dicerna Pharmaceuticals, Inc is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined.

Institutional Ownership by Quarter for Dicerna Pharmaceuticals (NASDAQ:DRNA)

Receive News & Stock Ratings for Dicerna Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.